1. Indications and Usage
\nNeovascular (Wet) Age-Related Macular Degeneration (nAMD):
\nTreatment of patients with nAMD.
\nNote: This indication improves visual acuity by inhibiting pathological angiogenesis and reducing retinal fluid.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intravitreal Injection ONLY. Must be administered by an ophthalmologist.
\nRecommended Dosage:
\nDose: 6 mg (0.05 mL) per injection.
\nSchedule:
\nInitial Phase: Once every 4 weeks (monthly) for the first 3 months.
\nMaintenance Phase: Once every 8\u201312 weeks thereafter, based on disease activity.
\nCritical Administration Instructions:
\nSterile Technique: Administer under sterile conditions with appropriate anesthesia and topical broad-spectrum bacteriostatic agent.
\nInjection Site: Typically injected into the vitreous cavity (e.g., 3\u20134 mm posterior to the limbus).
\n3. Mechanism of Action
\nSingle-Chain Antibody Fragment (scFv):
\nBrolucizumab is a humanized single-chain antibody fragment (approx. 26 kDa), which is significantly smaller than full-length antibodies (e.g., Ranibizumab\/Aflibercept).
\nVEGF Inhibition:
\nIt binds with high affinity to all isoforms of VEGF-A, preventing interaction with VEGFR-1 and VEGFR-2.
\nTherapeutic Result: Inhibits pathological angiogenesis and reduces vascular permeability (fluid leakage).
\nExtended Durability:
\nDue to its small molecular size and high solubility (allowing high drug concentration), it can penetrate retinal tissue more effectively and maintain therapeutic levels for longer periods, allowing for extended dosing intervals (up to 12 weeks).
\n4. Safety and Warnings
\nIntraocular Inflammation (IOI):
\nSerious intraocular inflammation, including retinal vasculitis and retinal vascular occlusion, has been reported.
\nAction: Monitor patients for signs of inflammation (e.g., floaters, vision loss, redness) after injection. If IOI is suspected, evaluate promptly and treat with corticosteroids.
\nEndophthalmitis and Retinal Detachment:
\nIntravitreal injections carry a risk of intraocular infection and retinal detachment.
\nIntraocular Pressure (IOP) Spikes:
\nIOP may increase transiently immediately following injection.
\nThromboembolic Events:
\nNon-fatal stroke, myocardial infarction, or vascular death may occur, although the risk is generally low.
\nContraindications:
\nActive or suspected ocular or periocular infections.
\nActive intraocular inflammation.
\nHypersensitivity to the drug.
\n5.Adverse Reactions
\nMost Common:
\nConjunctival hemorrhage, eye pain, vitreous floaters, vitreous detachment, and intraocular inflammation (including endophthalmitis, uveitis, and vitritis).
\n6.Drug Interactions
\nNo Clinical Significance:
\nNo specific drug-drug interaction studies have been conducted. Concomitant use with other anti-VEGF agents is generally avoided.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Brolucizumab.
\nAppearance: Clear, colorless to slightly yellowish solution.
\nPackaging: Single-dose vial (6 mg\/0.05 mL).
\nStorage: Store in a refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Do not freeze or shake.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u500d\u4f18\u9002 \u00ae(Beovu\u00ae)
\nGeneric Name: Brolucizumab
\nStrength: 19.8 mg (0.165 mL) per pre-filled syringe, 1 syringe per box
\nManufacturer: S.A. Alcon-Couvreur N.V.
\nMarketing Authorization Holder: Novartis AG
\nDomestic Responsible Entity: Novartis Pharmaceuticals (China) Co., Ltd.
\nApproval Date in China: May 27, 2025
\nRegistration Number: \u56fd\u836f\u51c6\u5b57SJ20250020
\nStorage: Store at 2\u00b0C\u20138\u00b0C, do not freeze. Keep in original carton to protect from light. Unopened blister may be stored below 25\u00b0C for up to 24 hours before administration. Refer to the package insert for full storage guidance.<\/p>\n
Price&Cost:Contact Us now for the best price of Brolucizumab \uff08Beovu\uff09<\/p>\n","protected":false},"featured_media":4183,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[80],"product_cat":[25],"product_tag":[],"class_list":["post-4182","product","type-product","status-publish","has-post-thumbnail","product_brand-novartis","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n